Trial record 1 of 1 for:    NCT01522443
Previous Study | Return to List | Next Study

Study of Cabozantinib (XL184) Versus Mitoxantrone Plus Prednisone in Men With Previously Treated Symptomatic Castration-resistant Prostate Cancer (COMET-2)

This study has been terminated.
(Stopped after the outcome of cabozantinib Phase 3 CRPC study XL184-307.)
Sponsor:
Information provided by (Responsible Party):
Exelixis
ClinicalTrials.gov Identifier:
NCT01522443
First received: January 13, 2012
Last updated: February 19, 2015
Last verified: February 2015
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been terminated.
  Study Completion Date: October 2014
  Primary Completion Date: October 2014 (Final data collection date for primary outcome measure)